Oxygenta Pharmaceutical Ltd.
Bombay Stock ExchangeTotal Valuation
Oxygenta Pharmaceutical Ltd. carries a market capitalization of 1.75B, placing it among publicly traded companies globally. Its enterprise value stands at 2.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.75B |
| Enterprise Value | 2.87B |
Share Statistics
Oxygenta Pharmaceutical Ltd. currently has 36.98M shares outstanding.
| Shares Outstanding | 36.98M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.59, and the price-to-book ratio stands at 4.86.
| PE Ratio | N/A |
| PS Ratio | 1.59 |
| PB Ratio | 4.86 |
| P/TBV Ratio | -4.21 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 2.54 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 75.88 |
Financial Position
Oxygenta Pharmaceutical Ltd. maintains a current ratio of 0.60, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -256.68, indicating conservative leverage, while an interest coverage ratio of -3.70 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.60 |
| Quick Ratio | 0.02 |
| Debt / Equity | -256.68 |
| Debt / EBITDA | -6.19 |
| Interest Coverage | -3.70 |
Financial Efficiency
| Return on Equity (ROE) | -47.24 |
| Return on Assets (ROA) | -17.31 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.55 |
Taxes
| Income Tax | -46.09M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Oxygenta Pharmaceutical Ltd.'s stock has declined approximately -59.29341% over the past 52 weeks. The 50-day moving average sits at 51.78, while the 200-day moving average is 56.16.
| Beta (5Y) | N/A |
| 52-Week Price Change | -59.29341% |
| 50-Day Moving Average | 51.78 |
| 200-Day Moving Average | 56.16 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Oxygenta Pharmaceutical Ltd. generated 1.13B in revenue and converted that into -175.83M in net income, yielding earnings per share of -4.73. EBITDA reached -176.89M, while operating income came in at -176.89M.
| Revenue | 1.13B |
| Gross Profit | -5.78M |
| Operating Income | -176.89M |
| Pretax Income | -221.92M |
| Net Income | -175.83M |
| EBITDA | -176.89M |
| EBIT | -176.89M |
| Earnings Per Share (EPS) | -4.73 |
Balance Sheet
Oxygenta Pharmaceutical Ltd. holds 21.49M in cash and equivalents against 1.10B in total debt, resulting in a net debt position of 1.09B. Total book value stands at 369.84M, with working capital of -346.67M providing operational flexibility.
| Cash & Cash Equivalents | 21.49M |
| Total Debt | 1.10B |
| Net Debt | 1.09B |
| Equity (Book Value) | 369.84M |
| Book Value Per Share | 9.95 |
| Working Capital | -346.67M |
Margins
Oxygenta Pharmaceutical Ltd. operates with a gross margin of -0.51, reflecting its pricing power and cost economics. The operating margin of -15.66 and net profit margin of -15.56 provide insight into operational efficiency.
| Gross Margin | -0.51 |
| Operating Margin | -15.66 |
| Pretax Margin | -19.64 |
| Profit Margin | -15.56 |
| EBITDA Margin | -15.66 |
Scores
Oxygenta Pharmaceutical Ltd. posts an Altman Z-Score of 0.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.77 |